First, the current results reinforce previous findings that GFAP and NEFL may have the potential not only to predict the overall risk of developing dementia (Walker et al., 2021, 2023; You et al., 2023) but also to serve as specific biomarkers to assess AD risk. This evidence concerns the gene GFAP and Alzheimer disease.